Does nicotinamide supplementation prevent skin cancer?
A study published in JAMA Dermatology explored the clinical efficacy of nicotinamide supplementation for skin cancer prevention. Patients exposed to oral nicotinamide, 500 mg, twice daily for longer than 30 days were matched to unexposed patients.
Nearly 4% of the matched cohort were solid organ transplant recipients. Overall, there was a 14% reduction in skin cancer risk. When nicotinamide was initiated after a first skin cancer, the risk reduction rose to 54%, although this benefit declined with initiation following subsequent skin cancers. This risk reduction was seen for skin cancers overall, BCC, and cSCC, with the greatest risk reduction seen for cSCC. Among solid organ transplant recipients, no overall significant risk reduction was observed, although early nicotinamide use was associated with reduced cSCC incidence.
Are nutritional supplements for skin care helpful, harmful, or placebo? Read more.
DermWorld Insights and Inquiries: The 2025 Allergen of the Year is to dye for
The “Allergen of the Year” announcement is always much anticipated in the world of contact dermatitis and patch testing. This year, the honor has gone to toluene-2,5-diamine sulfate (PTDS). PTDS is an aromatic amide that is used as a hair dye, textile dye, and in color photography. It was named the 2025 allergen of the year to not only highlight its potential as an allergen but also its potential as an alternative hair dye chemical for those who are allergic to paraphenylenediamine (PPD). As with so many other allergens, this chemical is not included in the FDA-approved standard screening series. It is also not included in many standard expanded screening series and therefore can be missed as a cause of allergy. Keep reading!
GLP-1 receptor agonists and isotretinoin
Authors of an article published in the Journal of Drugs in Dermatology highlighted considerations related to the use of GLP-1s when used concurrently with isotretinoin. The authors stated that GLP-1s may increase fertility, likely because of weight loss and hormonal changes. As women lose weight while taking GLP-1s, they often regain regulatory ovulatory cycles and have improved insulin sensitivity, both of which positively affect fertility, they wrote.
[Weighing in on glucagon-like peptide-1 receptor agonists in dermatology. Read more.]
They also noted that because GLP-1s delay gastric emptying, which has been shown to reduce the absorption of oral medications, isotretinoin may also not be absorbed as readily and may also reduce the potency of oral contraceptive pills. The authors advised advocating for more reliable forms of contraceptives and continued vigilance when initiating isotretinoin in patients on GLP-1s.
Adalimumab vs. adalimumab with methotrexate for psoriasis
Authors of a study published in JAMA Dermatology aimed to determine the effectiveness of using methotrexate with adalimumab in patients with plaque psoriasis. In this study, 1,553 patients received adalimumab 40 mg every other week while 231 patients with plaque psoriasis received adalimumab 40 mg every other week and methotrexate weekly.
[Do new psoriasis biologics have better safety profiles than adalimumab? Read more.]
At one year, drug survival for the monotherapy arm was 78.1% and the intervention arm was 79.1%, with no evidence of difference. PASI75 at one year and three years with adalimumab was 52.0% and 32.4%, respectively; in the intervention arm, PASI75 was 49.4% and 37.2%, respectively. There was no evidence of differences at one year and three years.
After weeks of confusion, CMS instructed all Medicare Administrative Contractors (MACs) to lift the hold and begin processing most claims with dates of service on or after Oct. 1, 2025. Additionally, without congressional action, Medicare will no longer pay for certain telehealth services after Oct. 1, 2025. Read more.
FDA issues warning letter to Naturich Cosmetique Labs
The FDA issued a warning letter to Naturich Cosmetique Labs citing significant violations of Current Good Manufacturing Practice regulations. The agency found deficiencies related to the manufacturer’s water and process validation systems, affecting its topical OTC products, which include skin protectants, acne treatments, and sunscreens.
Advertisement
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
